With-no-lysine kinase 4 (WNK4) regulates electrolyte homeostasis and blood pressure. WNK4 phosphorylates the kinases SPAK (Ste20-related proline alanine-rich kinase) and OSR1 (oxidative stress responsive kinase), which then phosphorylate and activate the renal Na-Cl cotransporter (NCC). WNK4 levels are regulated by binding to Kelch-like 3, targeting WNK4 for ubiquitylation and degradation. Phosphorylation of Kelch-like 3 by PKC or PKA downstream of AngII or vasopressin signaling, respectively, abrogates binding. We tested whether these pathways also affect WNK4 phosphorylation and activity. By tandem mass spectrometry and use of phosphositespecific antibodies, we identified five WNK4 sites (S47, S64, S1169, S1180, S1196) that are phosphorylated downstream of AngII signaling in cultured cells and in vitro by PKC and PKA. Phosphorylation at S64 and S1196 promoted phosphorylation of the WNK4 kinase T-loop at S332, which is required for kinase activation, and increased phosphorylation of SPAK. Volume depletion induced phosphorylation of these sites in vivo, predominantly in the distal convoluted tubule. Thus, AngII, in addition to increasing WNK4 levels, also modulates WNK4 kinase activity via phosphorylation of sites outside the kinase domain.
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renin-angiotensin-aldosterone system | NCC | hypertension | renal electrolyte transport | distal convoluted tubule T he distal portion of the mammalian nephron plays a key role in water, electrolyte, and blood pressure homeostasis. Mutations that alter normal renal Na-Cl homeostasis in this nephron segment modulate blood pressure and result in diverse electrolyte abnormalities (1). One such rare Mendelian trait is Pseudohypoaldosteronism type II (PHAII, OMIM 145260), which is characterized by hypertension, hyperkalemia, and metabolic acidosis; these features can be corrected by low doses of thiazide diuretics, inhibitors of the Na-Cl cotransporter of the distal convoluted tubule (NCC).
Genetic analysis of PHAII has revealed a previously unrecognized pathway that regulates blood pressure and electrolyte homeostasis in the distal nephron. Causative mutations have been found in four genes; two encode the serine-threonine kinases with-no-lysine 1 and 4 (WNK1 and WNK4) (2) , and two encode Cullin 3 (CUL3) and Kelch-like 3 (KLHL3), components of an E3-RING ubiquitin ligase complex (3) . At the time of the discovery of their causal relationship to this Mendelian disease, none of these proteins were known to play a role in electrolyte or blood pressure homeostasis. The biochemical mechanisms that link mutations to clinical phenoytpes are becoming understood. WNK4 is a Cl − -regulated kinase (4); when active, the kinase phosphorylates the kinases SPAK (Ste20-related proline alaninerich kinase) and OSR1 (oxidative stress responsive kinase), which in turn phosphorylate and activate the thiazide-sensitive Na-Cl cotransporter of the renal distal convoluted tubule (DCT). The phenotype of WNK4 knockout (WNK4-KO) mice recapitulates Gitelman syndrome (OMIM 263800), the mirror image of PHAII, suggesting that in vivo WNK4 is mainly present in the active state and that it plays a central role in NCC regulation (5) . In addition to this kinase-dependent regulation of the Na-Cl contransporter, WNK4 also regulates the activity of other mediators of distal renal electrolyte transport, for example, inhibiting the K + channel ROMK (6) . It thus appears that increased WNK4 activity can explain the increased Na-Cl reabsorption and hypertension seen in PHAII; the inhibition of ROMK can explain the inability to excrete K + , accounting for hyperkalemia (7) . Inhibition of NCC activity can reverse both the hypertension and hyperkalemia seen with PHAII.
Nonetheless, the mechanisms that regulate the activity of WNK4 were obscure until the discovery that mutations in CUL3 and KLHL3 can also cause PHAII (3, 8) . Subsequent work has shown that the kelch-like domain of KLHL3 specifically binds to WNK1 and WNK4, leading to their ubiquitylation and degradation (9, 10). Disease-causing dominant mutations in KLHL3 and CUL3 result in impaired binding and degradation of WNKs (9, 11, 12) . Conversely, disease-causing mutations in WNK4 are predominantly missense mutations in a short acidic domain (2) , which also prevent binding and ubiquitylation by the KLHL3-CUL3-RING complex; this acidic domain of WNK4 and WNK1 physically binds to KLHL3 (13) .
Recent work has shown that the binding of WNK4 by KLHL3 is regulated by Angiotensin II (AngII) via protein kinase C (PKC). Activation of PKC by AngII results in phosphorylation of S433 in the kelch domain, preventing WNK4 binding (14) . S433 is also targeted by PKA, presumably downstream of vasopressin
Significance
The kinase WNK4 (with-no-lysine kinase 4) is an important regulator of the Na-Cl cotransporter (NCC) in the renal distal convoluted tubule (DCT). Volume depletion induces angiotensin II, activating PKC, which prevents WNK4 degradation by phosphorylating the KLHL3/CUL3 ubiquitin ligase. We now show that PKC also directly phosphorylates WNK4 at multiple sites in cell culture. Phosphorylation of two of these sites, S64 and S1196, promotes increased WNK4 kinase activity by increasing autophosphorylation of the WNK4 T-loop at S332. Volume depletion also induces phosphorylation of WNK4-S64 in the DCT in vivo, promoting NCC activity. These findings provide insights into the mechanisms regulating activity of NCC and the promotion of renal Na-Cl reabsorption without concomitant K + secretion in volume depletion.
(AVP) (15) . The importance of this site is strongly supported by the observation that S433 is recurrently mutated in PHAII (3, 8) . Thus, the level of WNK4 clearly plays a critical role in regulation of electrolyte homeostasis, with single amino acid substitutions that result in increased WNK4 levels, leading to hypertension and hyperkalemia in humans. This pathogenic mechanism is supported by studies of BAC-transgenic PHAII mice, which show that mutant WNK4 levels are elevated in vivo (9, 11) . These findings nonetheless leave open the question of whether elevated levels are all that is necessary for increased WNK4 activity. Specifically, we considered whether PKC and PKA, in addition to phosphorylating KLHL3, might also impart effects by phosphorylating WNK4. Consistent with this possibility, we noted that WNK4 contains multiple consensus sites for PKC and PKA. We report herein systematic identification of phosphorylation sites in WNK4 and demonstration of their effects on WNK4's biochemical function.
Results WNK4 Phosphorylation Sites in HEK293 Cells. To examine steadystate Ser/Thr phosphorylation of WNK4, we expressed WNK4 tagged at the C terminus with the HA epitope in HEK293 cells and performed immunoprecipitation with anti-HA followed by mass spectrometry (MS) (16) . Three mapping experiments were performed, capturing 56% of the WNK4 protein sequence. Eighteen phosphorylation sites were reproducibly identified ( Fig.  S1A and Table S1 ). Four of these sites were at RRXS motifs, which are commonly phosphorylated by PKC and PKA (S64, S1169, S1180, S1196); the peptide containing an additional RRXS motif, at Ser-47, was not observed in MS. The three most C-terminal RRXS sites are clustered and conserved across all vertebrates and lie close to functionally important domains ( Fig. 1) , whereas the two N-terminal sites are clustered and conserved in vertebrates, other than fish (Fig. 1A) . Non-RRXS phosphorylation sites S1172 and S1176, which lie close to the C-terminal RRXS sites, and S332, which is the T-loop phosphorylation site required for activation of the kinase, are also highly conserved, whereas others are not at highly conserved positions in the protein (Table S1 ).
Activation of PKC and PKA Promotes Phosphorylation of WNK4-RRXS Sites. WNK4-HA-transfected COS-7 cells were treated acutely with the PKC inhibitor bisindolylmaleimide I (BIM), the PKC activator 12-O-tetradecanoylphorbol-13-acetate (TPA), or both. Changes in phosphorylation of WNK4-RRXS sites was examined by Western blotting using a well-established antibody with high specificity for RRXS P (Materials and Methods). A clear WNK4-RRXS P signal was detected in total cell extracts ( Fig. 2A) . TPA stimulation produced a significant increase in WNK4-RRXS phosphorylation ( Fig. 2A ) that was prevented in the presence of BIM. This finding strongly supports TPA-stimulated WNK4 phosphorylation because of activation of PKC rather than a different TPA-responsive kinase (17, 18) . Because PKA also phosphorylates the RRXS motif (19) , we probed the effect of pharmacologic inhibition and activation of PKA on WNK4-RRXS phosphorylation. Forskolin-induced PKA activation promoted WNK4-RRXS phosphorylation, which was prevented by coincubation with forskolin and PKA inhibitor, H89 (Fig. 2B ).
To further demonstrate the direct effect of PKC and PKA on WNK4-RRXS phosphorylation, in vitro kinase reactions were performed. Purified PKCα (one of the most highly expressed diacylglycerol-dependent PKC isoforms in kidney epithelium) or PKA efficiently phosphorylated WNK4-RRXS sites, demonstrating that WNK4 is a substrate for in vitro phosphorylation by both kinases (Fig. S1 B and C) .
Some of the RRXS sites in WNK4 have also been described as targets for serum glucocorticoid kinase 1 (SGK1)-mediated phosphorylation (20) (21) (22) . However, TPA or forskolin-induced increases in WNK4-RRXS phosphorylation were not prevented by SGK1 inhibition with GSK65039 (23) , suggesting that these effects were independent of SGK1 ( Fig. S1 D and E) .
PKC can be activated by AngII via downstream signaling via G q and phospholipase C (24) . COS-7 cells that express the AngII receptor show G q -dependent activation of PKC in response to AngII (25) . In these cells, we found that AngII promoted an increase in WNK4-RRXS phosphorylation within 10 min (Fig.  2C ). This increase was prevented with BIM, consistent with AngII inducing PKC-dependent phosphorylation (Fig. 2D ).
Phosphorylation of Individual Sites Probed with Phospho-Specific
Antibodies. We developed phosphosite-specific antibodies for each of the five RRXS sites in WNK4 (Materials and Methods). Each of these was highly specific for phosphorylation at the specified site, as shown in each case by the loss of signal when the targeted serine residue was mutated to alanine (Fig. S2A) .
Phosphorylation of each site was assessed in COS-7 and HEK293T cells following transfection with WNK4-HA and AT1 receptor and incubation with AngII, TPA (PKC activator), BIM (PKC inhibitor), forskolin (PKA activator), or H89 (PKA inhibitor). In both cell lines, treatment with AngII, TPA, and forskolin induced increased phosphorylation of all five sites ( Functional Relevance of WNK4-RRXS Phosphorylation. We next evaluated the effect of RRXS phosphorylation on WNK4's kinase activity using a well-known target, SPAK, as a substrate. COS-7 cells were transfected with SPAK and WNK4 phosphorylation mutants. Cells were incubated with H89 or forskolin to alter WNK4 phosphorylation and SPAK phosphorylation (S373) was assessed ( Fig. 4 A, C, and D, and Fig. S3 ). In the absence of WNK4, SPAK phosphorylation (pSPAK) levels were low and similar between H89-or forskolin-treated cells. However, in WNK4-transfected cells, pSPAK levels significantly increased despite the presence of H89, the PKA inhibitor, but were further augmented by forskolin (Fig. 4 A and D) . This forskolin-induced increase in pSPAK was not observed in cells transfected with kinase inactive WNK4 (WNK4-KI; D318A) (26) . Cotransfection of SPAK with a WNK4 (L319F mutant), which is not inhibitable by chloride (4, 27) , promoted an even stronger increase in pSPAK that was again augmented by forskolin treatment (Fig. 4 A, C, and D) . Mutation of all five serines in RRXS motifs to alanine (5A mutant) had no effect on WNK4 level, but drastically reduced the ability of WNK4 to phosphorylate SPAK. The 5A mutant showed pSPAK levels that were not significantly different from levels seen in the absence of WNK4, indicating a critical role of phosphorylation at these sites in modulation of WNK4's phosphorylation of SPAK. Furthermore, in the presence of this mutant, forskolin stimulation did not increase pSPAK, suggesting that phosphorylation of RRXS sites is necessary for this effect (Fig. 4 A, C, and D) .
Similarly, AngII stimulation of HEK293T cells expressing WNK4 and SPAK also showed augmented SPAK phosphorylation that was abolished by the WNK4-5A mutations (Fig. 4 B, E, and F). Interestingly, AngII did not induce increased pSPAK in cells cotransfected with WNK1 or WNK3 instead of WNK4 (Fig. S4 A  and B) , indicating that WNK4 is required for AngII-induced phosphorylation of SPAK (5) .
To explore the hierarchy of regulatory mechanisms, we tested the activity of the chloride-insensitive mutant (W4-L319F) in the 5A mutant. This sextuple mutant showed markedly lower phosphorylation of SPAK than the W4-L319 mutant (Fig. 4G) .
We next tested the importance of individual WNK4-RRXS phosphorylation sites on pSPAK and WNK4-RRXS P levels in forskolin-stimulated COS-7 cells. We found that the S64A and S1196A mutations were the only ones that significantly reduced both total RRXS phosphorylation and SPAK phosphorylation (Fig. 5 A and C and Fig. S3E ). When both mutations were present, the signal was virtually completely abolished. This observation, along with evidence that individual site mutations do not alter phosphorylation at other RRXS sites (Fig. S2A) , suggests that S64 and S1196 are the main sites of WNK4 phosphorylation detected by the RRXS P antibody and are the main sites required for phosphorylation of SPAK (Fig. 5 A and C) . Similar results demonstrating the primacy of phosphorylation at S64 and S1196 in WNK4-mediated phosphorylation of SPAK were observed in HEK293T cells stimulated with AngII (Fig. 5 B  and D and Fig. S3F ).
Phosphorylation of S64 and S1196 Regulates Phosphorylation of the WNK4 T-Loop. Activation of WNK4 kinase is known to require autophosphorylation of S332 of the T-loop in the kinase catalytic domain (4, 28) . We found that forskolin and AngII markedly increased T-loop phosphorylation, consistent with this being a primary mechanism by which forskolin and AngII increased downstream SPAK phosphorylation (Fig. 6) . Moreover, we found that this increased phosphorylation at S332 was abolished following mutation of all RRXS sites; this effect was mediated by alanine substitution at S64 and S1196. In addition, we observed that AngII-induced S332 phosphorylation was dependent on PKC activation. In contrast, the alanine mutants showed no impairment of WNK4 binding to SPAK or protein phosphatase 1 (PP1) (Fig. S4 C and D) . Thus, phosphorylation of these sites is implicated in the activation of WNK4 kinase activity rather than in WNK4's ability to bind to downstream targets or associated phosphatases.
Volume Depletion in Mice Promotes Phosphorylation of S64, S1169, S1180, and S1196. We used phosphosite-specific antibodies to test phosphorylation at specific sites in WNK4 in mouse kidney. Proteins from kidneys of WNK4-KO mice (5) were used to confirm the specificity of identified signals. We detected signal indicating phosphorylation at S64 and S1196 in Western blots of whole kidney protein extracts (Fig. S5A) , and also at S1169 and S1180 in blots of renal extracts immunoprecipitated with anti-WNK4 (Fig. S6) . We have not detected phosphorylation at S47 in either analysis.
We tested whether phosphorylation at these sites increases in response to AngII in the setting of volume depletion. As positive controls, we observed increased phosphorylation of T60 in NCC and increased levels of WNK4 (5, 14) . We observed significantly increased phosphorylation of S64, S1169, S1180, and S1196 in the volume-depleted group (Fig. 7A and Fig. S6A ). The ratio of pWNK4 to WNK4 was also significantly increased ( Fig. 7B and Fig. S6C ), indicating that WNK4 phosphorylation was stimulated and the increase was not simply the consequence of higher WNK4 levels. The increases in S64, S1169, S1180, and S1196 phosphorylation were not prevented by spironolactone (Fig. 7 A and B and Fig. S6 B and D) , despite effective blockade of aldosterone signaling, as shown by blunting of the induction of SGK1 expression (Fig. S7A) .
Volume Depletion Induces WNK4-S64 Phosphorylation Mainly in the DCT. To determine the renal cell types in which AngII increases phosphorylation of WNK4, we performed immunofluorescence microscopy using the anti-pS64 antibody, which gave a clear signal in volume-depleted wild-type mice that was eliminated in WNK4-KO mice (Fig. S5B) . Staining was identified exclusively in nephron segments that also expressed NCC, localizing this phosphorylation to the DCT. As previously reported, NCC membrane abundance increased in the high AngII state (29) . The staining patterns observed with the pS64-WNK4 and WNK4 antibodies were strikingly different between volume-depleted and volume-replete wild-type mice. In mice on a high salt diet, no pS64-WNK4 signal was detected in DCT cells (identified by NCC expression), whereas in volume-depleted mice, diffuse cytoplasmic staining with cytoplasmic puncta were clearly observed with anti-pS64 in all NCC-positive tubules (Fig. 7 C-F) . Interestingly, this pattern of cytoplasmic puncta has been observed by others when staining with antibodies to SPAK, OSR1, and WNK4 (30, 31) . We reproduced this pattern with antibodies to SPAK, OSR1, and pSPAK-S383 (Fig. S7 B-G) . Costaining with WNK4-pS64 and SPAK, OSR1, or pSPAK antibodies revealed colocalization of these signals (Fig. S7 H- 
J).
S64 and S1196 Phosphorylation in PHAII Mice. We tested phosphorylation at S64 and S1196 in kidney samples from mice carrying a transgene with a WNK4-PHAII mutation (32) . As expected, these mice had higher levels of WNK4 expression (Fig. 7 G  and H) . This result was accompanied by a higher level of S64 and S1196 phosphorylation. However, the fold-change in S64 phosphorylation and S1196 phosphorylation were, respectively, lower or similar to the fold-change observed for WNK4 total expression.
Discussion
The ability of increased renal salt reabsorption to cause hypertension is well established (1) . AngII has been shown to promote renal Na + reabsorption in an aldosterone-independent manner (33) (34) (35) , in part by increasing NCC activity (33) in a WNK4-dependent mechanism (5). We have previously shown that part of this mechanism is via increased levels of WNK4, because of AngII-PKC-mediated phosphorylation of KLHL3, which disrupts WNK4 binding and degradation (14) . Here we describe an additional mechanism contributing to AngII's effect on WNK4. Upon AngII stimulation, PKC phosphorylates WNK4 sites, which in turn increase phosphorylation of the T-loop of WNK4, increasing kinase activity and phosphorylation of downstream targets. Prior work has shown that WNK4 regulates diverse electrolyte flux mediators by kinase-dependent and independent mechanisms. The ability to regulate kinase activity independently of WNK4 level permits differential regulation of downstream targets (7) .
Of the two most critical PKC phosphorylation sites for kinase activation, serine 64 has not previously been reported, whereas S1196 has also been identified as a target of the aldosteroneinduced kinase SGK1 (20) (21) (22) . It seems clear that phosphorylation at this site is substantially attributable to direct phosphorylation by PKC/PKA because this site is directly phosphorylated by these enzymes in vitro, is regulated in cell culture by activators and inhibitors of PKC/PKA, and this site is phosphorylated in vivo by volume depletion despite inhibition of aldosterone signaling by spironolactone. We cannot exclude the possibility that PKC and PKA may phosphorylate additional sites in WNK4. For example, four phosphorylation sites identified by MS had variations of the PKC phosphorylation consensus sequence defined by basic amino acids at positions −3, −2, and +2, and in some cases, a hydrophobic amino acid at position +1 (36, 37) (Table S2) . . Band intensities were normalized establishing the WNK4-WT group as 100%. Data are means ± SEM. 5A, mutant in which the Ser residues of the five RRXS sites were substituted for Ala. *P < 0.01; # P < 0.05. Quantitation for RRXS P and SPAK blots is shown in Fig. S3 . Nevertheless, data show that elimination of S64 and S1196 is sufficient to prevent AngII-induced WNK4 activation.
It is interesting that the critical phosphorylation sites mediating the PKC/PKA-induced increase in WNK4 activity lie at the extreme amino and carboxyl-terminal ends of the protein. The N-terminal domain of WNK4 has previously been shown to have an inhibitory effect on WNK4 activity: when the N-terminal domain of WNK4 is substituted with the N-terminal domain of WNK3, the kinase becomes active in Xenopus laevis oocytes (38) . Similarly, phosphorylation of S1196 has been shown to diminish WNK4's inhibitory effect on NCC in X. laevis oocytes, perhaps because of the attenuation of a dominant-negative effect (21) . Our data suggest that phosphorylation of these sites via PKC/PKA relieves this inhibition via a mechanism that promotes phosphorylation of the T-loop of the kinase domain. This may occur via induction of a conformational change in WNK4, allowing access for intermolecular T-loop phosphorylation (39) , by reducing catalytic domain binding and inhibition by Cl − , or by modulating the binding of an as yet unidentified protein that alters WNK4 activation.
In addition to PKC, we show that PKA also regulates WNK4. This finding is interesting because phosphorylation and activity of SPAK/OSR1-NCC is also increased by AVP (30, 40, 41) . Binding of AVP to V2 receptors in renal epithelia leads to PKA activation; phosphorylation of WNK4 by PKA may be the next step mediating SPAK/OSR1-NCC activation.
PHAII is caused by increased activity of WNK1 and WNK4 (9, 11, 12) . We propose that WNK4-RRXS phosphorylation is important for its activity; thus, we predict that WNK4-RRXS sites are phosphorylated in PHAII. Consistently, we observed that mice carrying a WNK4-PHAII mutation (32) have higher WNK4 expression and phosphorylation at S64 and S1196 (Fig. 7) . The foldchange in pS1196, pS64, and WNK4 were similar; therefore, the higher phosphorylation observed may have been because of higher availability of substrate. Note that these sites are phosphorylated despite the low activity of the renin-angiotensin system. One possibility is that AVP-induced PKA activation may sustain RRXS phosphorylation. AVP levels have not been reported in PHAII patients or animals. However, AVP levels may be increased in states of increased salt reabsorption to maintain plasma isosmolarity, similar to the increased levels seen with high salt intake (42) (43) (44) . Additionally, high plasma [K + ] may also promote AVP secretion (45) . It is also intriguing that in PHAII, WNK4 remains activated despite hyperkalemia, because high plasma K + would be expected to inhibit WNK activity by modulation of intracellular chloride (31) .
Finally, these findings provide insight into the biochemical mechanism by which the kidney responds rapidly to reduce salt excretion in the setting of volume depletion (46) . NCC activation by AngII occurs within minutes of the stimulus onset (29) . AngII action, via WNK4 and SPAK, to activate NCC provides a response to volume depletion that is more rapid than the response via aldosterone, which requires time for adrenal induction of CYP11B2 mRNA and protein synthesis followed by aldosterone biosynthesis and its own induction of target genes in the kidney.
Materials and Methods
Cell Culture and Transient Transfection. COS-7 and HEK293T cells were used for transient expression of WNK4-HA, WNK4-FLAG, SPAK-HA, AT1R, WNK1-HA, and WNK3-HA. Cells were grown to 70-80% confluency and transfected with lipofectamine 2000 (Life Technologies). Forty-eight hours posttransfection, cells were lysed with a lysis buffer containing protease (Complete, Roche) and phosphatase inhibitors (Mixture 3, Sigma, P0044). Protein concentration was quantified by the BCA protein assay. Western blot assays and immunoprecipitation experiments were performed as described in SI Materials and Methods. Antibodies are also described. For treatment with BIM (Cell Signaling Technology #9841), TPA (Cell Signaling Technology #4174), H-89, Dihydrochloride (Cell Signaling Technology #9844), and forskolin (Cell Signaling Technology #3828), drugs were added to the culture media 30 min before lysis. The final concentration in the culture wells was 4 μM for BIM, 200 nM for TPA, 20 μM for H89, and 30 μM for forskolin. For acute treatment with AngII, cells were serumdepleted overnight and then incubated with 100 nM AngII for 30 min.
Mutations were introduced into the WNK4 clone by site directed mutagenesis using Pfu turbo DNA polymerase (Agilent) and confirmed by Sanger sequencing.
Phosphopeptide Enrichment and MS. The procedures followed were similar to those described previously (16) . Briefly, HA-tagged WNK4 was immunoprecipitated from lysates of transiently transfected HEK293 cells and then resolved on SDS/PAGE. Protein bands were excised from the gel and digested in a trypsin solution (20 μg/mL, sequence grade; Promega). Extracted peptides were applied to pre-equilibrated TiO 2 TopTip microspin columns (Glygen). Eluate fractions were injected onto the HPLC column (Atlantis, 100 μm × 150 mm; Waters) directly interfaced to an electrospray ionization-quadrupole time-of-flight (ESI-QTOF) mass spectrometer (Waters/Micromass Q-Tof Ultima). Data were analyzed with Mascot 2.1 with improved phosphopeptide scoring. Identified phosphopeptides were confirmed by manual inspection of the spectra (for details see SI Materials and Methods).
Mouse Studies. Animal studies were approved by the Yale Institutional Animal Care and Use Committee (protocol no. 10018). Most studies were performed in wild-type C57BL/6 mice. WNK4-knockout and PHAII-transgenic mouse strains were also used (5, 32) . Volume-depletion model. Both the control and volume-depleted groups were kept on high salt diet [8% (wt/wt) NaCl] for ∼7 d before the beginning of treatment with furosemide. Half of the mice were then switched to low sodium diet (0.01-0.02% Na , every 12 h for 3 d) (47) . The control group was injected with saline and kept on high salt diet. Before being killed, mice were anesthetized with 100 mg·kg −1 ketamine plus 10 mg·kg −1 xylazine, the right renal artery was ligated, and the right kidney was collected and flash-frozen in liquid nitrogen. Mice were then perfused as described in SI Materials and Methods and the left kidney was harvested and treated as indicated for immunofluorescence (SI Materials and Methods). Spironolactone treatment. The volume-depletion protocol was carried out as described in the previous section, but spironolactone was administered in both groups, control and furosemide-treated. Spironolactone treatment began 2 d before the first injection of furosemide and continued throughout experiment. Mice were injected every 12 h (intraperitoneally) with spironolactone (40 mg·kg −1 ·d −1 ) (48).
Statistical Analysis. For comparison between two groups, unpaired Student's t test (two tailed) was used. For comparison between multiple groups, ANOVA tests were performed, followed by Tukey post hoc tests. A difference between groups was considered significant when P < 0.05. 
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